Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 17/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 17/20 | 0.38 |
| ▸ | THRA | P10827 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16717221 | 1.00 | KMT2A (0.40) | KMT2ABRD4CREBBPTHRATHRB | |
| SCHEMBL16717568 | 0.88 | BRD4 (0.36) | KMT2ABRD4CREBBPTHRB | |
| SCHEMBL16717195 | 0.88 | BRD4 (0.48) | BRD4CREBBP | |
| SCHEMBL16717194 | 0.88 | BRD4 (0.48) | BRD4CREBBP | |
| SCHEMBL17004877 | 0.88 | BRD4 (0.36) | KMT2ABRD4CREBBPTHRB | |
| SCHEMBL17004899 | 0.85 | NOTUM (0.36) | KMT2ABRD4CREBBP | |
| SCHEMBL16729496 | 0.85 | NOTUM (0.36) | KMT2ABRD4CREBBP | |
| SCHEMBL28344473 | 0.80 | BRD4 (0.36) | BRD4CREBBP | |
| SCHEMBL28344475 | 0.80 | BRD4 (0.36) | BRD4CREBBP | |
| SCHEMBL28341827 | 0.79 | BRD4 (0.34) | KMT2ABRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230061891-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11111229-B2 | Tetrahydroquinoline compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| EP-3799872-A1 | TETRAHYDROQUINOLINE DERIVATIVES FOR USE AS BET INHIBITORS | Forma Therapeutics, Inc. (US) | 2021-04-07 | — | — | EP | disclosed |
| EP-3071203-B1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS INC (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20200369642-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2020-11-26 | — | — | US | disclosed |
| US-10611750-B2 | Tetrahydroquinoline compositions as bet bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2020-04-07 | — | — | US | disclosed |
| CN-110627770-A | Tetrahydroquinoline compositions as BET bromodomain inhibitors | 福马疗法公司 | 2019-12-31 | — | — | CN | disclosed |
| US-10336722-B2 | Tetrahydroquinoline compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20190127347-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2019-05-02 | — | — | US | disclosed |
| US-20180215766-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2018-08-02 | — | — | US | disclosed |
| EP-3071203-A2 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | Forma Therapeutics, Inc. (US) | 2016-09-28 | — | — | EP | disclosed |
| US-20160256448-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160257692-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-9388161-B2 | Tetrahydroquinoline compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150232445-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2015-08-20 | — | — | US | disclosed |
| WO-2015074064-A2 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BAIR KENNETH W (US) | 2015-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160256448-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | KMT2A 221/4885BRD4 1/4885CREBBP 194/4885 |
| US-20180215766-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | KMT2A 221/4885BRD4 1/4885CREBBP 194/4885 |
| US-20190127347-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | KMT2A 221/4885BRD4 1/4885CREBBP 194/4885 |
| US-10336722-B2 | Tetrahydroquinoline compositions as BET bromodomain inhibitors | BRD4, BRD3, BRD1 | KMT2A 221/4885BRD4 1/4885CREBBP 194/4885 |
| US-11111229-B2 | Tetrahydroquinoline compositions as BET bromodomain inhibitors | BRD4, BRD3, BRD1 | KMT2A 221/4885BRD4 1/4885CREBBP 194/4885 |
| US-20200369642-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | KMT2A 221/4885BRD4 1/4885CREBBP 194/4885 |
| US-10611750-B2 | Tetrahydroquinoline compositions as bet bromodomain inhibitors | BRD4, BRD3, BRD1 | KMT2A 221/4885BRD4 1/4885CREBBP 194/4885 |
| US-20150232445-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | KMT2A 221/4885BRD4 1/4885CREBBP 194/4885 |
| US-20230061891-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | KMT2A 221/4885BRD4 1/4885CREBBP 194/4885 |
| US-20160257692-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | KMT2A 221/4885BRD4 1/4885CREBBP 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.